Clinical Trial: A Dose-exploration Study of EDP167 in HoFH

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489209) titled 'A Dose-exploration Study of EDP167 in HoFH' on March 19.

Brief Summary: EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in HoFH patients to evaluate the efficacy and safety and PK/PD profiles of multiple EDP167 injections.

Study Start Date: Feb. 06

Study Type: INTERVENTIONAL

Condition: Homozygous Familial Hypercholesterolemia (HoFH)

Intervention: DRUG: EDP167

EDP167 sc injection

Recruitment Status: RECRUITING

Sponsor: Eddingpharm (Zhuhai) Co., Ltd.

Published by HT Digital Content Services ...